摘要
2016年,类风湿关节炎、干燥综合征、痛风等多种风湿病的诊治指南再次更新,"长程管理、达标治疗"的理念已经从类风湿关节炎,逐渐渗透到系统性红斑狼疮、痛风、脊柱关节炎等多种疾病的治疗决策中。新型生物制剂不断涌现,传统抗风湿药物和生物制剂的应用和转换原则越来越清晰明确,风湿免疫病的诊断和治疗方法越来越规范。
In 2016, many guidelines for the diagnosis and treatment of rheumatoid arthritis, Sjogren syndrome, gout and other rheumatic diseases updated again. The concepts of ＂long range management, treat to target＂ which originated from the management of rheumatoid arthritis, have gradually infiltrated into the treatment decisions about systemic lupus erythematosus,gout,spondyloarthritis and other rheumatic diseases. New biological agents continue to emerge. The exchange principles from traditional disease modifying anti-rheumatic drugs to biological agents have been more and more organized. The diagnosis and treatment methods of rheumatic disease have been more and more standardized.
出处
《临床荟萃》
CAS
2017年第2期146-151,共6页
Clinical Focus
关键词
关节炎
类风湿
红斑狼疮
干燥综合征
痛风
风湿病
诊断
治疗进展
arthritis, rheumatoid
lupus erythematosus
Sjogren syndrome
gout
rheumatic disease
diagnosis
treatment progress
